Atea Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $401.8M
- Price
- $5.01
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.18%
- Volume
- 264.8K
About
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Quick stats
Shares outstanding80.2M
Computed float61.1M
Float / shares76.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001593899
Websitehttps://www.ateapharma.com
AI Summary
AI-generated1/14
minorneutralother
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Atea Pharmaceuticals will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 12:20 p.m. EDT in New York.
CEO and founder Jean-Pierre Sommadossi, together with other members of Atea management, will deliver the presentation, with a live webcast available and an archive posted on the company website for at least 90 days.
Atea's Phase 3 program is evaluating a fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C, while AT-587 is in Phase 1 development for hepatitis E. The release contains no new clinical or financial data.